Investor Profile: ARCH Venture Partners — Thesis, Cheque Size & How to Apply

Founders researching ARCH Venture Partners funding are looking at a firm that does not just fund biotech companies — it creates them. ARCH is one of the largest early-stage technology venture firms in the US, and its defining move is co-founding companies with leading scientists and entrepreneurs, commercialising breakthroughs from academic institutions, corporate research groups and national laboratories. Since 1986 it has built a track record that includes Illumina, Alnylam and Juno Therapeutics.

Thesis and focus areas

ARCH's thesis is blunt: great science, translated aggressively into great companies. The firm invests primarily in companies it co-founds, concentrating on life sciences and physical sciences — spanning infectious disease, immunology, mental health, genomic and biological tools, data sciences, diagnostics and curative therapies. It describes itself as a recognised leader in commercialising technologies developed at academic institutions, corporate research groups and national laboratories. As managing director Steve Gillis put it: ARCH is "still willing to sit down with a scientist with a lab notebook to develop and translate great science into great companies" — a line that captures how early the firm is prepared to engage.

Cheque size and stage

ARCH invests at the earliest stages and scales with its winners. Managing director Kristina Burow has said the firm invests "whether it's fifty thousand dollars or hundreds of millions" — a $50,000-to-hundreds-of-millions range that is unusually explicit for a venture firm. The capital base backs it up: ARCH Venture Fund X and ARCH Venture Fund X Overage closed in 2020 with a combined $1.46 billion for early-stage biotechnology, following Fund IX ($1.1 billion, 2016) and Fund VIII ($560 million, 2014). Total assets under management were reported at $9 billion in 2022.

Notable portfolio

Early-stage ARCH investments have included Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Receptos, Agios Pharmaceuticals, Vir Biotechnology, Sage Therapeutics, bluebird bio, Codiak Biosciences, Denali Therapeutics, GRAIL, Karuna Therapeutics, Beam Therapeutics, Lyell Immunopharma, Sana Biotechnology, Twist Bioscience, Gossamer Bio, Fate Therapeutics, Array BioPharma, deCODE Genetics and Homology Medicines — a portfolio crowded with category-defining names.

Team

ARCH was founded in 1986 by Steven Lazarus, Clinton Bybee, Keith Crandell and Robert Nelsen. Its managing directors include co-founders Robert Nelsen and Keith Crandell alongside Kristina Burow, Mark McDonnell, Steve Gillis and Paul Thurk.

How to apply for funding

ARCH does not run a public application portal. Given its company-creation model, the realistic route is a direct approach through the firm's website (archventure.com) or — better — a warm introduction from a scientist, entrepreneur or investor in ARCH's orbit. Founders with deep, differentiated science can expect ARCH to engage far earlier than most VCs, sometimes before a company exists at all.